Ocean Biomedical, Inc. Common Stock
OCEA
OCEA was delisted on the 23rd of April, 2025.
22 hedge funds and large institutions have $2.01M invested in Ocean Biomedical, Inc. Common Stock in 2024 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 3 closing their positions.
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
5% more funds holding
Funds holding: 21 → 22 (+1)
0% more call options, than puts
Call options by funds: $2K | Put options by funds: $2K
42% less capital invested
Capital invested by funds: $3.46M → $2.01M (-$1.46M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$43.3K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$27K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$16.1K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$4.95K |
| 5 |
Citigroup
New York
|
+$3.16K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$18.2K |
| 2 |
Millennium Management
New York
|
-$2.1K |
| 3 |
NA
Nordwand Advisors
Radnor,
Pennsylvania
|
-$1.96K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.3K |
| 5 |
AA
ACT Advisors
Asheville,
North Carolina
|
-$622 |
OCEA Hedge Fund Activity: Q4 2024 in Review
22 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Ocean Biomedical, Inc. Common Stock (OCEA) for Q4 2024, worth a combined $2.01M — down 42% from $3.46M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new OCEA positions and 3 closed out — a net gain of 1 holder — while 7 added to existing stakes and 4 trimmed.
The largest buyer was UBS Group, adding an estimated $43.3K. The largest seller was XTX Topco, exiting entirely with an estimated $18.2K sold.
- 22 institutional investors held Ocean Biomedical, Inc. Common Stock (OCEA) as of Q4 2024, up from 21 in Q3 2024.
- Funds reported $2.01M of Ocean Biomedical, Inc. Common Stock stock for Q4 2024, down 42% quarter-over-quarter.
- 4 funds opened new Ocean Biomedical, Inc. Common Stock positions in Q4 2024 and 3 closed out, a net change of +1 holder.
- The largest Ocean Biomedical, Inc. Common Stock buyer in Q4 2024 was UBS Group, an estimated $43.3K added.
- The largest Ocean Biomedical, Inc. Common Stock seller in Q4 2024 was XTX Topco, an estimated $18.2K sold.
Based on aggregated 13F filings for Q4 2024.